Bristol-Myers Squibb to Post Select Investigational Compound Data Updates on Company Website

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) will begin posting updates about select Phase 1 and 2 investigational compounds on the company website at www.bms.com/research/investigational. The updates will communicate an overview of new data presented at medical meetings or data published in scientific journals. The first update will be posted on Saturday, April 17, 2010.

Media and investors interested in receiving notifications when investigational compound updates are posted may subscribe to Bristol-Myers Squibb’s “Investigational Compound News” RSS feed at www.bms.com/news/pages/rss_alerts.aspx.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.



CONTACT:

Bristol-Myers Squibb Company
Media:
Sonia Choi, 609-252-5132
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Other Health  General Health

MEDIA:

Logo
 Logo

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.